Show simple item record

Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study

dc.contributor.authorLencioni, R.en_US
dc.contributor.authorMarrero, J.en_US
dc.contributor.authorVenook, A.en_US
dc.contributor.authorYe, S. -L.en_US
dc.contributor.authorKudo, M.en_US
dc.date.accessioned2011-01-31T17:39:05Z
dc.date.available2011-09-06T16:03:06Zen_US
dc.date.issued2010-07en_US
dc.identifier.citationLencioni, R.; Marrero, J.; Venook, A.; Ye, S.-L.; Kudo, M.; (2010). "Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study." International Journal of Clinical Practice 64(8): 1034-1041. <http://hdl.handle.net/2027.42/79194>en_US
dc.identifier.issn1368-5031en_US
dc.identifier.issn1742-1241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/79194
dc.description.abstractHepatocellular carcinoma (HCC) is a complicated condition influenced by multiple confounding factors, making optimum patient management extremely challenging. Ethnicity, stage at diagnosis, comorbidities and tumour morphology affect outcomes and vary from region to region, and there is no common language to assess patient prognosis and make treatment recommendations. Despite recent efforts to reduce the incidence of HCC, most patients present with unresectable disease. Non-surgical treatments include ablation, transarterial chemoembolisation and the multikinase inhibitor, sorafenib, but their effects in all patient subgroups are not known and further information is needed to optimise the use of these treatments.The Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) study (ClinicalTrials.gov identifier NCT00812175; http://clinicaltrials.gov/ ) is an ongoing global, prospective, non-interventional study of patients with unresectable HCC who are eligible for systemic therapy and for whom the decision has been taken to treat with sorafenib under real-life practice conditions. The aim of this study is to evaluate the safety and efficacy of sorafenib in different subgroups, especially Child-Pugh B where data are limited.This study will recruit 3000 patients from > 40 countries and follow them for approximately 5 years to compile a large and robust database of information that will be used to analyse local, regional and global differences in baseline characteristics, disease aetiology, treatment practice patterns and treatment outcomes, with a view to improve the knowledge base used to guide physician treatment decisions and to improve patient outcomes.en_US
dc.format.extent543269 bytes
dc.format.extent3106 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.titleDesign and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) studyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumMultidisciplinary Liver Tumor Clinic, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDivision of Diagnostic Imaging and Intervention, Department of Liver Transplantation, Hepatology and Infectious Diseases, Pisa University School of Medicine, Pisa, Italyen_US
dc.contributor.affiliationotherUniversity of California, San Francisco, CA, USAen_US
dc.contributor.affiliationotherLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, Chinaen_US
dc.contributor.affiliationotherDepartment of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japanen_US
dc.identifier.pmid20642705en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/79194/1/j.1742-1241.2010.02414.x.pdf
dc.identifier.doi10.1111/j.1742-1241.2010.02414.xen_US
dc.identifier.sourceInternational Journal of Clinical Practiceen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.